Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastati...

Full description

Bibliographic Details
Main Authors: Katjana S. Schwab, Glenn Kristiansen, Hans H. Schild, Stefanie E.A. Held, Annkristin Heine, Peter Brossart
Format: Article
Language:English
Published: Karger Publishers 2018-01-01
Series:Case Reports in Oncology
Subjects:
Nivolumab
Ipilimumab
Squamous cell carcinoma
Anti-PD-1 inhibitor
Anti-CTLA4 antibody
Anti-programmed cell death protein 1 inhibitor
Online Access:https://www.karger.com/Article/FullText/485562

Internet

https://www.karger.com/Article/FullText/485562

Similar Items